Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid Drop
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-18. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Contraction in state Medicaid rolls forces revenue rebalancing toward higher-margin ACA Marketplace policies, altering CNC's medical loss ratio.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factCentene reported Q2 2026 adjusted EPS of $2.51, reversing a net loss in the prior-year period. |
| What else was confirmed? | Reported factManagement projects total Medicaid membership will contract by 8% to 9% during full-year 2026. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for CNC; the latest is dated 2026-09-16. |
| What would change the assessment? | UnknownState Medicaid redetermination data updates — State-level enrollment filings confirming whether Medicaid attrition has bottomed. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Centene reported Q2 2026 adjusted EPS of $2.51, reversing a net loss in the prior-year period.
- · Management projects total Medicaid membership will contract by 8% to 9% during full-year 2026.
- · Operating profit recovery was driven by improved medical cost trends and margin gains in Commercial Marketplace and Medicare lines.
Public research record
Research framework · page evidenceCompleted event assessment
medical loss ratio stabilization and commercial marketplace margin expansion
| Type | Claim | Scope |
|---|---|---|
| Assumption | Centene reported Q2 2026 adjusted EPS of $2.51, reversing a net loss in the prior-year period. | 2026-09-18 |
| Interpretation | medical loss ratio stabilization and commercial marketplace margin expansion | CNC |
Countercase, invalidators, and sources
Commercial Marketplace margins expand further, driving 2026 full-year EPS revisions above consensus.
- · State Medicaid redetermination data updates — State-level enrollment filings confirming whether Medicaid attrition has bottomed.
- Can Centene Sustain Its Turnaround Amid Membership Pressure? · 2026-09-17
What remains unresolved
- Base path
- CNC maintains profitability as Medicaid membership stabilizes at the lower range of guidance.
- Adverse path
- Utilization spikes in Medicare Advantage reverse second-quarter medical cost efficiency gains.
- Supportive path
- Commercial Marketplace margins expand further, driving 2026 full-year EPS revisions above consensus.
- · State Medicaid redetermination data updates — State-level enrollment filings confirming whether Medicaid attrition has bottomed.this week
Evidence
- Can Centene Sustain Its Turnaround Amid Membership Pressure?2026-09-17
“Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior... expects Medicaid membership to decline 8%-9% in 2026”
Supports: Centene Q2 adjusted EPS reached $2.51 while 2026 Medicaid membership is guided down 8%-9%.